AI Article Synopsis

Article Abstract

Drug-resistant bacterial pathogens are a serious threat to global health, and antibacterial lysins are at the forefront of innovative treatments for these life-threatening infections. While lysins' general mechanism of action is well understood, the design principles that might enable engineering of performance-enhanced variants are still being formulated. Here, we report a detailed analysis of molecular determinants underlying the efficacy of lysostaphin, a canonical anti-MRSA (methicillin-resistant ) lysin. Systematic analysis of bacterial binding, growth inhibition, lysis kinetics, and therapeutic efficacy revealed that binding affinity, and not inherent catalytic firepower, is the dominant driver of lysostaphin efficacy. This insight enabled electrostatic affinity tuning of lysostaphin to produce a single point mutant that manifested dramatically enhanced processivity and lysis kinetics and trended toward improved efficacy. More generally, these studies provide important insights into the complex relationships between lysin electrostatics, bacterial targeting, cell lysis efficiency, and efficacy. The lessons learned may enable engineering of other high-performance antibacterial biocatalysts.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097437PMC
http://dx.doi.org/10.1128/AAC.02199-20DOI Listing

Publication Analysis

Top Keywords

lysis kinetics
12
affinity tuning
8
tuning lysostaphin
8
enable engineering
8
efficacy
6
electrostatic-mediated affinity
4
lysostaphin
4
lysostaphin accelerates
4
bacterial
4
accelerates bacterial
4

Similar Publications

Chimeric antigen receptor T cells (CART) targeting CD19 through CD28.ζ signaling induce rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB.ζ-CART.

View Article and Find Full Text PDF

Background: Lipid vesicles, especially those utilizing biocompatible materials like chitosan (CHIT), hold significant promise for enhancing the stability and release characteristics of drugs such as indomethacin (IND), effectively overcoming the drawbacks associated with conventional drug formulations.

Objectives: This study seeks to develop and characterize novel lipid vesicles composed of phosphatidylcholine and CHIT that encapsulate indomethacin (IND-ves), as well as to evaluate their in vitro hemocompatibility.

Methods: The systems encapsulating IND were prepared using a molecular droplet self-assembly technique, involving the dissolution of lipids, cholesterol, and indomethacin in ethanol, followed by sonication and the gradual incorporation of a CHIT solution to form stable vesicular structures.

View Article and Find Full Text PDF
Article Synopsis
  • PAMAM dendrimers, known for their structural versatility and customizable surfaces, are being investigated for biomedical uses, but their interactions with blood can disrupt normal clotting and pose health risks.
  • The study focused on how low-generation PAMAM dendrimers affect fibrin clot formation dynamics, including clot structure and resistance to breakdown, using various methods and blood samples.
  • Notably, certain dendrimers like G2-NH and G4-NH hindered clot formation and altered clot properties significantly, while G3.5-COOH showed minimal impact, suggesting it could be a safer option for medical applications.
View Article and Find Full Text PDF
Article Synopsis
  • Acinetobacter baumannii, especially the carbapenem-resistant strains (CRAB), is a critical pathogen linked to antimicrobial resistance (AMR) and is prioritized by the WHO.
  • Phage therapy is being explored as a potential treatment for CRAB infections due to increasing resistance to conventional antibiotics.
  • A newly isolated lytic phage, vAbaIN10, exhibits effective lytic activity against CRAB in various conditions and shows promise in advancing treatment options for multidrug-resistant infections.
View Article and Find Full Text PDF

Dependence of clot structure and fibrinolysis on apixaban and clotting activator.

Res Pract Thromb Haemost

November 2024

Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA.

Background: Anticoagulants prevent the formation of potentially fatal blood clots. Apixaban is a direct oral anticoagulant that inhibits factor (F)Xa, thereby impeding the conversion of prothrombin into thrombin and the formation of blood clots. Blood clots are held together by fibrin networks that must be broken down (fibrinolysis) to restore blood flow.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!